Angelo.....you are correct. I am assuming there are going to be bonuses paid for any approvals the company receives up until the bonus package ends in 2018. and also the annual fee for keeping the applications going.
if these actually cost us nothing to hold and get approved, of course why not keep them. but if I am right and we see a bonus paid for Seroquel and Glucophage by say 2QE are you going to feel the same way ? I dont have a problem paying bonuses for any drug which eventually is commercialized. but based on what I read, I think we will see they are going to be paying bonuses from any approvals up through 2018 and if so, I sure hope they can make money off of them.
I think Cysonic agreed with that concept in his last post. which is all I am saying. I may be wrong....maybe all these approvals wont cost us a dime. but if they do I sure hope they can partner them else its a bad slap for us investors who are still paying for them.
we wont know the answer to this one until the QE reports come out and we see if any bonuses are paid for the approvals. Its just a hunch I have.
News 
Market Data 
Discover 
AI
